Bio Gene Technology : Appendix 4C - 30 June 2022

Evergreen Garden Care

ForEvergreen's evaluation of Bio-Geneproducts has continued with a focus on Flavocide in Europe and the UK, and on Qcide in Australian and New Zealand markets. Product development and target uses reflect the differences in markets with the European programs focused on indoor and outdoor uses for flying and crawling insect control, and Evergreen ANZ focusing initially on outdoor home garden uses. Regulatory pathways for the active ingredients are now well understood with product development and end-use-productregistration becoming more of a focus.

Flavocide grain storage project

Results from the latest stage of testing with Flavocide in grain storage have been collated and presented in a final project report to the GRDC. The residual efficacy study that was an integral part of this stage of the project successfully demonstrated the effectiveness of Flavocide combination treatments in controlling five of the key stored grain pests (Lesser grain borer, Flour beetle, Saw-toothedgrain beetle, Flat grain beetle and Rice weevil) for

Bio-GeneTechnology Limited

ABN: 32 071 735 950

Level 6, 400 Collins Street, Melbourne, VIC 3000

Bio-Gene/ClarkeMosquito Control program advancing to next phase

Collaboration with Evergreen Garden Care to target specific market segments in Europe & ANZ Regulatory authorities in key markets now engaged on registration pathways

Patent application submitted in Australia for Qcide™ use for flying insect control

•

•

•

•

onlyBio-GeneTechnology Limited (ASX: BGT, 'Bio-Gene'or 'the Company'), an agtech development company enabling the next generation of novel insecticides, today announced an update on its activities for the quarter ending 30 June 2022 and to date.

useBio-GeneChief Executive Officer and Managing Director, Richard Jagger said: "This last quarter has been one of continued progress on key fronts including our development programs with commercial partners; registration activity; and manufacturing requirements. We have been focusing on developing the relationships and activities with Clarke and Evergreen to ensure we are on a clear path towards product development and registration. In addition, we have been working with other companies to further test our technology in their laboratories for applications relevant to their individual expertise. During the quarter we announced the decision of BASF not to

continue their participation in the Stored Grain Pest program with Flavocide™. BASF advised us that this project did personalnot meet its current global strategic focus, and therefore could not continue their support to the program. Whilst disappointing, it should be expected that some companies will not always have a strategic alignment with Bio-

Gene, which is why we always aim to have multiple companies testing our products for any given market. Currently, we are working with several other potential partners who are very well equipped to develop our technology for the global grain protection market. Whilst BASF was to be a newcomer to this market segment, these companies are already major players in this market space and have highlighted to us the value of new Modes of Action becoming available to this application. We will continue to work with these companies aimed at securing mutually beneficial collaboration arrangements."

Clarke Mosquito Control Agreement

Bio-Geneand Clarke have commenced regular project team meetings to jointly develop and register Flavocide in the USA. This followed the signing in April 2022 of a licence and development agreement aimed at commercialising Flavocide for use in professional public health mosquito control markets in the USA and Cayman Islands. Initial meetings are focussed on the next phase of designing and testing of Flavocide as an outdoor mosquito adulticide roduct. Bio-Geneis also working closely with Clarke's regulatory staff to ensure program alignment with USA EPA

requirements for registration of active ingredient and end-useformulations.

JUNE 2022 QUARTERLY UPDATE

ASX ANNOUNCEMENT 28 JULY 2022

up to a 9-month period. These and other efficacy results would form the basis for Flavocide product label recommendations for control of the major pest species impacting grain storage. The focus will now shift to a closer onlyconsideration of the regulatory requirements for this use pattern in Australia and overseas, including the data required to support minimum residue levels (MRLs) in grain commodities. Discussions are continuing with the GRDC, and with other potential commercial partners with an interest in this market segment, with a view to further evaluating the market potential and how current collaborative programs and registration enabling studies will assist

the commercialisation of Flavocide as a grain protectant.

Other Commercial Partner Discussions

Bio-Gene continues to actively engage with other potential commercial partners to promote our technology and support evaluation programs targeting uses in multiple market segments. We continue to work with companies usealready testing our technology and identify new companies to work with us under Material Transfer Agreements to test our products in new market applications. Our goal is to continue to create agreements like those developed

with Clarke and Evergreen to open new commercial pathways for our products.

Intellectual Property

In June 2022 Bio-Gene submitted an application for a provisional patent in Australia entitled "Improved Pesticidal Compositions and Pest Control Methods". The specification relates to the use of Qcide and other β-diketones used

in combination with a pyrethroid or pyrethrin compound for the control of flying insects. Examples included control personalof mosquito and fly species including resistant strains with evidence supporting synergy of these combinations.

Examination of other patent applications is continuing both in Australia and in countries around the world, and in the meantime Bio-Gene is continuing to generate data to support additional patent applications to add value to Bio-Gene and our commercial partners.

Development of Active Ingredient International Registration Package

The regulatory data requirements for registration of Qcide and Flavocide in key markets have been established through comprehensive data gap analyses undertaken by regulatory consultants. This has led to the initiation of the next phase of studies in the areas of mammalian toxicity, ecotoxicity, environmental fate and product chemistry. Contact with regulatory agencies in key target jurisdictions, including the USA, has been initiated in collaboration with our regulatory consultants and, in some cases, the assistance of our commercial partners. In particular, based on conversations with the EPA in the United States, we have made a submission for a Biochemical classification of Flavocide. This step has implications for the data requirements for registration, with the aim of streamlining this process. We expect on-going dialogue with the EPA over coming months as they review our submission.

ForManufacturing

Flavocide: The five-batch production program undertaken with Boron Molecular is now complete, with all five batches meeting target specification in terms of active ingredient level and impurity profile. As part of this project, standard operating procedures (SOP) for the manufacture of Flavocide have been fully documented, supported by detailed analysis of various stages of the process. These data are critical components of our Active Ingredient registration dossier.

Projects to further improve the economics of production of Flavocide are continuing aimed at identifying and investigating process improvements, alternative lower-costnon-core reagents, and waste recovery/recycle opportunities. This includes a project with CSIRO investigating treatment of the waste stream to recover a key reagent for re-use in an important stage of the flavesone synthesis process. This aims to reduce waste disposal

Bio-Gene Technology Limited

ABN: 32 071 735 950

Level 6, 400 Collins Street, Melbourne, VIC 3000

costs, but more importantly, to reduce the overall cost of raw materials to produce Flavocide, thereby improving the market competitiveness and profitability for Bio-Gene and our partners.

onlyQcide: Trees have re-coppiced well following the latest harvest in February with the next harvest planned for September/October 2022. Analysis of oil from the February on-farm experimentation, including another 5-batch production run, again confirmed very consistent processing conditions and oil profile that meet our established Qcide oil specification. The formal project with James Cook University (JCU) engineering is nearing completion, with the final report pending that will detail the laboratory testing program undertaken to determine optimum extraction conditions. Going forward, JCU will continue to assist on a less formal basis with on-farm experimentation relating to oil extraction improvements as well as energy efficiency evaluations aimed at production cost savings. A project with a commercial plant tissue culture service provider has been initiated to

usestablish the superior tree lines currently being maintained at JCU Cairns, with a view to produce seedlings to improve quality and expand the current plantation area.

Company Presentations

This quarter also saw Bio-Gene represented at several important industry and scientific conferences that included:

- Pesticon AEPMA (Australian Environmental Pest Managers Association) National Conference

	(www.aepma.com.au/conference);
personal
-	Australian Grain Storage Protection Conference (Grain Storage & Protection Conference 2022 (eventsair.com));
	and
-	International Conference on Urban Pests (www.icup.org.uk).

Bio-Gene also presented at the Pac Partners annual Agfood investor conference in June.

We continue to build on our social media interactions with regular communications on company activities and global issues relevant to our business development activities. These and on-going updates can be found on our ocial media pages:

• LinkedIn: -https://au.linkedin.com/company/bio-genetechnology

• Twitter: -https://twitter.com/biogenetechltd

The Company will continue to focus on investor briefings and industry presentations over the course of the year.

Cash Position

As at 30 June 2022, Bio-Gene held $6.3 million in cash, which based on current plans, provides the Company with sufficient cash to operate well beyond 12 months.

Approved for release by the Board of Directors.

	- ENDS -
or further information, please contact:
For
Bio-Gene Technology Limited:		Media/investor relations:
Richard Jagger	Roger McPherson	Rudi Michelson
Chief Executive Officer	CFO & Company Secretary	Monsoon Communications
P: 03 9068 1062	P: 03 9068 1062	P: 03 9620 3333
E:[e-mail]	E:[e-mail]	E:[e-mail]

Bio-Gene Technology Limited

ABN: 32 071 735 950

Level 6, 400 Collins Street, Melbourne, VIC 3000

About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel onlyplatform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g., kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for i secticide manufacturers in applications across crop protection and storage, public health, consumer applications and animal health. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions, working with industry leaders across key market segments.

FlavocideTM

For usepersonal

and QcideTM are trademarks of Bio-Gene Technology Limited.

Bio-Gene Technology Limited

ABN: 32 071 735 950

Level 6, 400 Collins Street, Melbourne, VIC 3000

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Appendix 4C

Quarterly cash flow report for entities

subject to Listing Rule 4.7B

Name of entity

Bio-Gene Technology Limited

ABN			Quarter ended ("current quarter")
32 071 735 950	30 June 2022
Consolidated statement of cash flows	Current quarter	Year to date
			$A'000	$A'000
1.	Cash flows from operating activities
1.1	Receipts from customers	63	467
1.2	Payments for
	(a)	research and development	(495)	(1,470)
	(b)	commercialisation expenses	(135)	(377)
	(c)	management administration expenses	(28)	(176)
	(d)	directors' expenses	(63)	(239)
	(e)	professional services	-	(60)
	(f)	intellectual property	(62)	(194)
	(g)	administration and corporate costs (see	(116)	(511)
		note 6)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	19	53
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	514
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating	(817)	(1,993)
	activities

ASX Listing Rules Appendix 4C (17/07/20)	Page 1
+ See chapter 19 of the ASX Listing Rules for defined terms.